The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Pathological mechanisms and therapeutic strategies for Alzheimer’s disease
Open accessAbstract
Alzheimer's disease is a rather complex neurodegenerative disease, which is attributed to a combination of multiple factors. Among the many pathological pathways, synaptic dysfunctions, such as synapses loss and deficits in synaptic plasticity, were thought to be strongly associated with cognitive decline. The deficiencies in various sorts of neurotransmissions are responsible for the multifarious neurodegenerative symptoms in Alzheimer's disease, for example, the cholinergic and glutamatergic deficits for cognitive decline, the excitatory and inhibitory neurotransmission dyshomeostasis for synaptic plasticity deficits and epileptiform symptoms, and the monoamine neurotransmission for neuropsychiatric symptoms. Amyloid cascade hypothesis is the most popular pathological theory to explain Alzheimer's disease pathogenesis and attracts considerable attention. Multiple lines of genetic and pathological evidence support the predominant role of amyloid beta in Alzheimer's disease pathology. Neurofibrillary tangles assembled by microtubule-associated protein tau are other important histopathological characteristics in Alzheimer's disease brains. Cascade of tau toxicity was proved to lead to neuron damage, neuroinflammation and oxidative stress in brain. Ageing is the main risk factor of neurodegenerative diseases, and is associated with inflammation, oxidative stress, reduced metabolism, endocrine insufficiencies and organ failures. These aging related risk factors were also proved to be some of the risk factors contributing to Alzheimer's disease. In Alzheimer's disease drug development, many good therapeutic strategies have been investigated in clinical evaluations. However, complex mechanism of Alzheimer's disease and the interplay among different pathological factors call for the come out of all-powerful therapies with multiple curing functions. This review seeks to summarize some of the representative treatments targeting different pathological pathways currently under clinical evaluations. Multi-target therapies as an emerging strategy for Alzheimer's disease treatment will be highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“Ageing facilitates and accelerates cognitive impairment and is the most predominant risk factor for neurodegenerative diseases, including AD (Hou et al., 2019).”
BackgroundSynaptic Plasticity: Multiple Forms, Functions, and Mechanisms
Citri, A., & Malenka, R. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301559 · Cited by 2,323 · cited 1×
“The predominant hypothesis is that the postsynaptic calcium signal within dendritic spines dictates whether LTP or LTD triggered, with LTP requiring a calcium increase beyond a threshold and LTD requiring a modest calcium increase (Malenka and Nicoll, 1993; Citri and Malenka, 2008).”
BackgroundNeuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Alzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“APOE isoforms influence AD by regulating Aβ clearance differently, with the APOE ε4 allele markedly increases AD risk while the APOE ε2 allele decreases Aβ accumulation (Castellano et al., 2011).”
BackgroundBlock of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987
NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms
Malenka, R. C., & Nicoll, R. A. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90197-t · Cited by 904
Xiao, Y., Ma, B., McElheny, D., Parthasarathy, S., Long, F., Hoshi, M., Nussinov, R., & Ishii, Y. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2991 · Cited by 818
Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease
Donato, A. J., Machin, D. R., & Lesniewski, L. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312563 · Cited by 688
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662
Building the Neuronal Microtubule Cytoskeleton
Kapitein, L. C., & Hoogenraad, C. C. (2015) · Neuron · doi:10.1016/j.neuron.2015.05.046 · Cited by 650
A vicious cycle of β amyloid−dependent neuronal hyperactivation
Zott, B., Simon, M. M., Hong, W., Unger, F., Chen-Engerer, H.-J., Frosch, M. P., Sakmann, B., Walsh, D. M., & Konnerth, A. (2019) · Science · doi:10.1126/science.aay0198 · Cited by 640
Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0677 · Cited by 637
Tau protein kinases: Involvement in Alzheimer's disease
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631
Reiner, A., & Levitz, J. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.018 · Cited by 631
Glycogen synthase kinase-3 signaling in Alzheimer's disease
Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 615
Ageing, age-related diseases and oxidative stress: What to do next?
Luo, J., Mills, K., le Cessie, S., Noordam, R., & van Heemst, D. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100982 · Cited by 581 · cited 1×
“In aged population, there are dysregulations of the immune system and decreased metabolism levels with higher risk of neuroinflammation, oxidative stress and vascular diseases as well as diabetes (Donato et al., 2018; Rea et al., 2018; Luo et al., 2020).”
BackgroundSavelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Microtubules and Microtubule-Associated Proteins
Goodson, H. V., & Jonasson, E. M. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022608 · Cited by 579
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
GABA receptor mechanisms in the central nervous system
Sivilotti, L., & Nistri, A. (1991) · Progress in Neurobiology · doi:10.1016/0301-0082(91)90036-z · Cited by 554
Wang, J.-Z., Xia, Y.-Y., Grundke-Iqbal, I., & Iqbal, K. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129031 · Cited by 532
Mann, D. M. A., & Esiri, M. M. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90019-1 · Cited by 471
Overlap Between Pathology of Alzheimer Disease and Vascular Dementia
Kalaria, R. N., & Ballard, C. (1999) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199912003-00017 · Cited by 470
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459
Theofilas, P., Ehrenberg, A. J., Dunlop, S., Di Lorenzo Alho, A. T., Nguy, A., Leite, R. E. P., Rodriguez, R. D., Mejia, M. B., Suemoto, C. K., Ferretti-Rebustini, R. E. D. L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2362 · Cited by 416
Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms
Bentahir, M., Nyabi, O., Verhamme, J., Tolia, A., Horré, K., Wiltfang, J., Esselmann, H., & De Strooper, B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03578.x · Cited by 415
Sex and the development of Alzheimer's disease
Pike, C. J. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23827 · Cited by 402
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
Bennett, C. F., Krainer, A. R., & Cleveland, D. W. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050501 · Cited by 353
Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models
Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352
Jacob, C. P., Koutsilieri, E., Bartl, J., Neuen-Jacob, E., Arzberger, T., Zander, N., Ravid, R., Roggendorf, W., Riederer, P., & Grünblatt, E. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11113 · Cited by 317
Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
Gao, Y., Tan, L., Yu, J.-T., & Tan, L. (2018) · Current Alzheimer Research · doi:10.2174/1567205014666170417111859 · Cited by 315
LTP requires a reserve pool of glutamate receptors independent of subunit type
Granger, A. J., Shi, Y., Lu, W., Cerpas, M., & Nicoll, R. A. (2013) · Nature · doi:10.1038/nature11775 · Cited by 313
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Rice, H. C., de Malmazet, D., Schreurs, A., Frere, S., Van Molle, I., Volkov, A. N., Creemers, E., Vertkin, I., Nys, J., Ranaivoson, F. M., et al. (2019) · Science · doi:10.1126/science.aao4827 · Cited by 281
Changes in Nicotinic and Muscarinic Cholinergic Receptors in Alzheimer‐Type Dementia
Shimohama, S., Taniguchi, T., Fujiwara, M., & Kameyama, M. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb12960.x · Cited by 257
Diabetes and Alzheimer’s disease crosstalk
Baglietto-Vargas, D., Shi, J., Yaeger, D. M., Ager, R., & LaFerla, F. M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.005 · Cited by 256
Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease
Pooler, A. M., Polydoro, M., Maury, E. A., Nicholls, S. B., Reddy, S. M., Wegmann, S., William, C., Saqran, L., Cagsal-Getkin, O., Pitstick, R., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0199-x · Cited by 236
Glutathione redox imbalance in brain disorders
Gu, F., Chauhan, V., & Chauhan, A. (2015) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000134 · Cited by 236
Lewis, J., & Dickson, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1507-z · Cited by 220
Seizures in Elderly Patients with Dementia: Epidemiology and Management
Mendez, M. F., & Lim, G. T. H. (2003) · Drugs & Aging · doi:10.2165/00002512-200320110-00001 · Cited by 219
Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
Govindpani, K., Calvo-Flores Guzmán, B., Vinnakota, C., Waldvogel, H., Faull, R., & Kwakowsky, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081813 · Cited by 208
GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
Dynamic learning and memory, synaptic plasticity and neurogenesis: an update
Stuchlík, A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00106 · Cited by 188
Grothe, M., Heinsen, H., & Teipel, S. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.018 · Cited by 178
NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies
Zhang, C., Wang, Y., Wang, D., Zhang, J., & Zhang, F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00083 · Cited by 174
Diversity of structure and function of GABAB receptors: a complexity of GABAB-mediated signaling
TERUNUMA, M. (2018) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.94.026 · Cited by 173
Association of epileptiform abnormalities and seizures in Alzheimer disease.
Lam, A. D., Sarkis, R. A., Pellerin, K. R., Jing, J., Dworetzky, B. A., Hoch, D. B., Jacobs, C. S., Lee, J. W., Weisholtz, D. S., Zepeda, R., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010612 · Cited by 172 · cited 1×
“Epileptiform discharge was observed in 22% of AD patients with no history or risk factors for epilepsy (Lam et al., 2020).”
BackgroundSynapse loss and progress of Alzheimer’s disease -A network model
Kashyap, G., Bapat, D., Das, D., Gowaikar, R., Amritkar, R. E., Rangarajan, G., Ravindranath, V., & Ambika, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-43076-y · Cited by 172
The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer’s Disease
Rudy, C. C., Hunsberger, H. C., Weitzner, D. S., & Reed, M. N. (2015) · Aging and disease · doi:10.14336/ad.2014.0423 · Cited by 171
Kumar, A., & Singh, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00206 · Cited by 170
NEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE
Bondareff, W., Mountjoy, C. Q., Roth, M., Rossor, M. N., Iversen, L. L., Reynolds, G. P., & Hauser, D. L. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701040-00005 · Cited by 166 · cited 1×
“There have been reports of significant Locus coeruleus (LC) noradrenergic neurodegeneration, such as neuron loss and atrophy, associated with the severity of cognitive dysfunction in AD (Bondareff et al., 1987; Theofilas et al., 2017).”
BackgroundDopaminergic Modulation of Cortical Plasticity in Alzheimer’s Disease Patients
Koch, G., Lorenzo, F. D., Bonnì, S., Giacobbe, V., Bozzali, M., Caltagirone, C., & Martorana, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.119 · Cited by 158
The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease
Mitchell, R. A., Herrmann, N., & Lanctôt, K. L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00161.x · Cited by 153
Zhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H. M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X. Y., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 141
Choline acetyltransferase activity and cognitive domain scores of Alzheimer’s patients☆
Pappas, B. A., Bayley, P. J., Bui, B. K., Hansen, L. A., & Thal, L. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00090-7 · Cited by 131
Targeting Synaptic Plasticity in Experimental Models of Alzheimer’s Disease
Mango, D., Saidi, A., Cisale, G. Y., Feligioni, M., Corbo, M., & Nisticò, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00778 · Cited by 121
Emerging Link between Alzheimer’s Disease and Homeostatic Synaptic Plasticity
Jang, S.-S., & Chung, H. J. (2016) · Neural Plasticity · doi:10.1155/2016/7969272 · Cited by 113
Larsson, S. C., & Markus, H. S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180288 · Cited by 107
Emerging pathways driving early synaptic pathology in Alzheimer's disease
Briggs, C. A., Chakroborty, S., & Stutzmann, G. E. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.088 · Cited by 101
Wang, T., Liu, X.-H., Guan, J. Z., Ge, S., Wu, M., Lin, J., & Yang, L.-R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.076 · Cited by 100
Ardestani, P. M., Evans, A. K., Yi, B., Nguyen, T., Coutellier, L. D., & Shamloo, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.01.010 · Cited by 92
Altered Brain Serotonin Transporter and Associated Glucose Metabolism in Alzheimer Disease
Ouchi, Y., Yoshikawa, E., Futatsubashi, M., Yagi, S., Ueki, T., & Nakamura, K. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063008 · Cited by 91
Cordella, A., Krashia, P., Nobili, A., Pignataro, A., La Barbera, L., Viscomi, M. T., Valzania, A., Keller, F., Ammassari-Teule, M., Mercuri, N. B., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.006 · Cited by 82
Orexin and Alzheimer’s Disease
Liguori, C. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_50 · Cited by 81
GABA receptor function and pharmacology in epilepsy and status epilepticus
Jones, D. M., & MACDONALD, R. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00015-2 · Cited by 77
Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Talarico, G., Trebbastoni, A., Bruno, G., & de Lena, C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180702144644 · Cited by 77
A half century of γ-aminobutyric acid
Smart, T. G., & Stephenson, F. A. (2019) · Brain and Neuroscience Advances · doi:10.1177/2398212819858249 · Cited by 74
Natural Polyphenols in the Treatment of Alzheimer’s Disease
Syarifah-Noratiqah, S.-B., Naina-Mohamed, I., Zulfarina, M. S., & Qodriyah, H. M. S. (2017) · Current Drug Targets · doi:10.2174/1389450118666170328122527 · Cited by 68
Cell Loss from the Nucleus Basalis of Meynert in Alzheimer's Disease
Doucette, R., Fisman, M., Hachinski, V. C., & Mersky, H. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100037070 · Cited by 67
Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Vignini, A., Giulietti, A., Nanetti, L., Raffaelli, F., Giusti, L., Mazzanti, L., & Provinciali, L. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309030003 · Cited by 57
Beyond pathology: APP, brain development and Alzheimer's disease
Soldano, A., & Hassan, B. A. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.02.003 · Cited by 54
Ramos‐Rodríguez, J. J., Gil, S. M., Rey-Brea, R., Berrocoso, E., & García-Alloza, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079947 · Cited by 49
Messing, L., Decker, J. M., Joseph, M., Mandelkow�, E., & Mandelkow, E.-M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.024 · Cited by 48
Roles of sigma-1 receptors in Alzheimer's disease.
Jin, J., Fang, M., Zhao, Y., & Liu, X. (2015) · PubMed · Cited by 47
Jia, J., Jia, J.-M., Zhou, W., et al. (2004) · PubMed · Cited by 47
High prevalence of parkinsonism in patients with MCI or mild Alzheimer's disease
Sasaki, S. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3054 · Cited by 32
Optogenetic stimulation of serotonin nuclei retrieve the lost memory in Alzheimer's disease
Bostancıklıoğlu, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29077 · Cited by 32
Lan, M., Liu, J.-S., Wu, Y.-S., Peng, C.-H., & Chang, Y. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.03.038 · Cited by 27
Disruption of gamma–delta relationship related to working memory deficits in first-episode psychosis
Missonnier, P., Prévot, A., Herrmann, F. R., Ventura, J., Padée, A., & Merlo, M. C. G. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02126-5 · Cited by 22
Ju, Y., Chakravarty, H., & Tam, K. Y. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00464 · Cited by 16
Self-citationJu, Y., & Tam, K. Y. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108354 · Cited by 13
Self-citationBianco, O. A. F. M., Manzine, P. R., Nascimento, C. M. C., Vale, F. A. C., Pavarini, S. C. I., & Cominetti, M. R. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215001842 · Cited by 11
A second family with familial AD and the V717L APP mutation has a later age at onset
Godbolt, A. K., Beck, J. A., Collinge, J. C., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000197791.53828.2c · Cited by 10
Cited by
Teleanu, R. I., Niculescu, A.-G., Roza, E., Vladâcenco, O., Grumezescu, A. M., & Teleanu, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115954 · Cited by 596
Mokra, D., Joskova, M., & Mokry, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010340 · Cited by 355
New insight into neurological degeneration: Inflammatory cytokines and blood–brain barrier
Yang, J., Ran, M., Li, H., Lin, Y., Ma, K., Yang, Y., Fu, X., & Yang, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1013933 · Cited by 279
Meftah, S., & Gan, J. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1129036 · Cited by 205
Di Benedetto, G., Burgaletto, C., Bellanca, C. M., Munafò, A., Bernardini, R., & Cantarella, G. (2022) · Cells · doi:10.3390/cells11172728 · Cited by 189
“Over the years, several hypotheses have been proposed to unveil the complex patho‐ logical mechanisms underlying AD‐related neurodegeneration [23].”
Background
Metadata
- Authors
- Tam, K., & Ju, Y.
- Venue
- Neural Regeneration Research
- Publisher
- Medknow
- Published
- 2022
- Volume
- 17
- Issue
- 3
- Pages
- 543
- ISSN
- 1673-5374 (ISSN-L)
- OpenAlex
- W3187573306
- Cited by
- 395
- References
- 96
- FWCI
- 32.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.